Captor Therapeutics Spolka Akcyjna (CTX.WA)
PLN 32.2
(1.58%)
PLN 32.2
(1.58%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1.24 Million PLN | -61.45% |
| 2022 | 3.23 Million PLN | 10.03% |
| 2021 | 2.94 Million PLN | -56.2% |
| 2020 | 6.71 Million PLN | 17.08% |
| 2019 | 5.73 Million PLN | -22.24% |
| 2018 | 7.37 Million PLN | 411.3% |
| 2017 | 1.44 Million PLN | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 3.03 Million PLN | 0.0% |
| 2024 Q1 | 822 Thousand PLN | 0.0% |
| 2023 Q3 | 1.59 Million PLN | -27.19% |
| 2023 Q2 | 2.19 Million PLN | -18.6% |
| 2023 FY | 1.24 Million PLN | -61.45% |
| 2023 Q4 | 1.24 Million PLN | -21.87% |
| 2023 Q1 | 2.69 Million PLN | -16.75% |
| 2022 Q1 | 2.29 Million PLN | -21.97% |
| 2022 Q4 | 3.23 Million PLN | -21.33% |
| 2022 FY | 3.23 Million PLN | 10.03% |
| 2022 Q3 | 4.11 Million PLN | 188.97% |
| 2022 Q2 | 1.42 Million PLN | -37.97% |
| 2021 Q2 | 4.98 Million PLN | 2228.5% |
| 2021 FY | 2.94 Million PLN | -56.2% |
| 2021 Q1 | 214 Thousand PLN | -96.81% |
| 2021 Q4 | 2.94 Million PLN | -23.87% |
| 2021 Q3 | 3.86 Million PLN | -22.5% |
| 2020 FY | 6.71 Million PLN | 17.08% |
| 2020 Q2 | 5.23 Million PLN | 0.0% |
| 2020 Q4 | 6.71 Million PLN | 0.0% |
| 2019 FY | 5.73 Million PLN | -22.24% |
| 2019 Q4 | 5.73 Million PLN | 0.0% |
| 2018 FY | 7.37 Million PLN | 411.3% |
| 2017 FY | 1.44 Million PLN | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Bioceltix S.A. | 76.33 Thousand PLN | -1533.632% |
| BIOTON S.A. | 12.67 Million PLN | 90.163% |
| Mabion S.A. | 2.94 Million PLN | 57.7% |
| Molecure S.A. | 4.97 Million PLN | 74.939% |
| NanoGroup S.A. | - PLN | -Infinity% |
| Pharmena S.A. | 114 Thousand PLN | -993.86% |
| Poltreg S.A. | 7.8 Million PLN | 84.015% |
| Pure Biologics Spólka Akcyjna | 12.85 Million PLN | 90.297% |
| Ryvu Therapeutics S.A. | 365 Thousand PLN | -241.644% |
| Synthaverse S.A. | 61.2 Million PLN | 97.962% |
| Urteste S.A. | 312 Thousand PLN | -299.679% |